US2012328568A1PendingUtilityA1

Compositions and uses of lectins

Assignee: CUMMINGS RICHARD DPriority: Feb 12, 2010Filed: Feb 11, 2011Published: Dec 27, 2012
Est. expiryFeb 12, 2030(~3.6 yrs left)· nominal 20-yr term from priority
A61P 31/12A61P 31/00A61P 31/04A61P 31/10A61K 45/06A61P 31/18A61K 38/1732A61K 38/178A61P 31/16A61P 31/22A61P 31/14Y02A50/30
27
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.

Claims

exact text as granted — not AI-modified
1 . Use of a purified galectin to kill bacteria and other pathogens. 
     
     
         2 . A method of treating or preventing an infectious disease comprising administering a purified lectin to a subject at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection. 
     
     
         3 . The method of  claim 2 , wherein the subject is a human subject. 
     
     
         4 . The method of  claim 2 , wherein the lectin is Gal-4, Gal-7, Gal-8, Gal-9 or active fragments thereof. 
     
     
         5 . The method of  claim 4 , wherein a fragment of Gal-4, Gal-8, and Gal-9 comprises a C-terminal carbohydrate recognition domain. 
     
     
         6 . The method of  claim 4 , wherein a fragment of Gal-9 comprises an N-terminal carbohydrate recognition domain. 
     
     
         7 . The method of  claim 6 , wherein the human blood group antigen is A, B, H, an Rh glycoprotein or combination thereof 
     
     
         8 . The method of  claim 2 , wherein the subject is diagnosed with blood type B. 
     
     
         9 . The method of  claim 2 , wherein the pathogen is a bacteria, virus, or fungus. 
     
     
         10 . The method of  claim 9 , wherein the bacteria is selected from the group consisting of  Acinetobacter baumannii, Bordetella pertussis, Burkholderia cepacia, Burkholderia pseudomallei, Burkholderia mallei, Campylobacter jejuni, Campylobacter coli, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Francisella tularensis, Haemophilus influenzae, Haemophilus ducreyi, Helicobacter pylori, Klebsiella pneumoniae, Legionella penumophila, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Neisseria    meningitidis, Pasteurella multocida, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi, Serratia marcescens, Shigella flexneri, Shigella boydii, Shigella sonnei, Shigella dysenteriae, Stenotrophomonas maltophilia, Vibrio cholerae , and  Chlamydia pneumoniae.    
     
     
         11 . The method of  claim 2 , wherein the purified galectin is administered in combination with one or more antibiotic agents. 
     
     
         12 . The method of  claim 11 , wherein the antibiotic agent is sulfanilamide, sulfarnethizole, sulfamethoxazole, sulfapyridine, trimethoprim, pyrimethamine, nalidixic acids, norfloxacin, ciproflaxin, cinoxacin, dapsone, enoxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, ofloxacin, pefloxacin, sparfloxacin, trovafloxacin, penicillins (amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, hetacillin, oxacillin, mezlocillin, penicillin G, penicillin V, piperacillin), cephalosporins (cefacetrile, cefadroxil, cefalexin, cefaloglycin, cefalonium, cefaloridin, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid, ceforanide, cefprozil, cefuroxime, cefuzonam, cefinetazole, cefoteta, cefoxitin, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefotiam, cefpimizole, cefpiramide, cefpodoxime, cefteram, ceftibuten, ceftiofur, ceftiolen, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefepime), moxolactam, carbapenems (imipenem, ertapenem, meropenem) monobactams (aztreonam)oxytetracycline, chlortetracycline, clomocycline, demeclocycline, tetracycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, chloramphenicol, amikacin, gentamicin, framycetin, kanamycin, neomicin, neomycin, netilmicin, streptomycin, tobramycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, telithromycin, polymyxin-B, colistin, bacitracin, tyrothricin notrifurantoin, furazolidone, metronidazole, tinidazole, Isoniazid, pyrazinamide, ethionamide, nystatin, amphotericin-B, hamycin, miconazole, clotrimazole, ketoconazole, fluconazole, rifampacin, lincomycin, clindamycin, spectinomycin,chloramphenicol, clindamycin, fosfomycin, loracarbef, metronidazole, nitrofurantoin, polymyxin B, polymyxin B sulfate, procain, spectinomycin, tinidazole, trimethoprim, ramoplanin, teicoplanin, vancomycin, trimethoprim, sulfamethoxazole, and/or nitrofurantoin. 
     
     
         13 . The method of  claim 9 , wherein the virus is influenza A virus including subtype H1N1, influenza B virus, influenza C virus, rotavirus A, rotavirus B, rotavirus C, rotavirus D, rotavirus E, SARS coronavirus, human adenovirus types (HAdV-1 to 55), human papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, parvovirus B19, molluscum contagiosum virus, JC virus (JCV), BK virus, Merkel cell polyomavirus, coxsackie A virus, norovirus, Rubella virus, lymphocytic choriomeningitis virus (LCMV), yellow fever virus, measles virus, mumps virus, respiratory syncytial virus, rinderpest virus, California encephalitis virus, hantavirus, rabies virus, ebola virus, marburg virus, herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, roseolovirus, or Kaposi's sarcoma-associated herpesvirus, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E or human immunodeficiency virus (HIV). 
     
     
         14 . The method of  claim 2 , wherein the purified galectin is administered in combination with one or more antiviral agents. 
     
     
         15 . The method of  claim 13 , wherein the antiviral agent is abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir,darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir (Tamiflu), peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin , raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir (Valtrex), valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir (Relenza), and/or zidovudine (AZT). 
     
     
         16 . A pharmaceutical composition comprising a Gal-4, Gal-7, Gal-8, Gal-9 or active fragments thereof provided the galectin comprises a C-terminal carbohydrate recognition domain.

Join the waitlist — get patent alerts

Track US2012328568A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.